Payment overview · 2025
General Payments
$727.79
43 reported records · 14 companies
Healthcare provider profile · identity verified
Kurtis Kostan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TYLER, TX · NPI 1134516172
Verified facts
What the public records show
CMS Open Payments records show Kurtis Kostan, MD received $727.79 in general payments during 2025 across 43 reported records.
Novo Nordisk Inc accounted for 25.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Ozempic, Rybelsus.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $184.73 | 25.4% | 11 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.65 | 9.7% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $68.60 | 9.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.93 | 8.5% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.60 | 7.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.51 | 7.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $47.94 | 6.6% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $43.27 | 6.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $34.77 | 4.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $33.30 | 4.6% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.75 | 2.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.74 | 2.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $16.73 | 2.3% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.27 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.79 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $98.32 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $72.13 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $72.13 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $61.93 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $53.51 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $44.64 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $43.27 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.38 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $34.77 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.49 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $16.45 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 77 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 90 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
77 | 19 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 312 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 70 |
| Losartan Potassium | Losartan Potassium | 219 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 216 | 72 |
| Mounjaro | Tirzepatide | 185 | 28 |
| Gabapentin | Gabapentin | 170 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 165 | 59 |
| Trazodone Hcl | Trazodone Hcl | 156 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 143 | 39 |
| Alprazolam | Alprazolam | 135 | 27 |
| Lisinopril | Lisinopril | 129 | 47 |
| Omeprazole | Omeprazole | 129 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 127 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 121 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 40 |
| Metformin Hcl Er | Metformin Hcl | 110 | 29 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 28 |
| Carvedilol | Carvedilol | 102 | 29 |
| Meloxicam | Meloxicam | 100 | 28 |
| Montelukast Sodium | Montelukast Sodium | 97 | 30 |
| Azithromycin | Azithromycin | 95 | 76 |
| Ozempic | Semaglutide | 90 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 21 |
| Bupropion Xl | Bupropion Hcl | 85 | 26 |
| Eliquis | Apixaban | 77 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 76 | 30 |
| Clonidine Hcl | Clonidine Hcl | 74 | 16 |
| Jardiance | Empagliflozin | 70 | 13 |
| Buspirone Hcl | Buspirone Hcl | 69 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 18 |
| Ondansetron Odt | Ondansetron | 68 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 18 |
| Furosemide | Furosemide | 65 | 22 |
| Spironolactone | Spironolactone | 65 | 21 |
| Metformin Hcl | Metformin Hcl | 61 | 19 |
| Sertraline Hcl | Sertraline Hcl | 61 | 19 |
| Clonazepam | Clonazepam | 60 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 12 |
| Ezetimibe | Ezetimibe | 58 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 12 |
| Famotidine | Famotidine | 51 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 43 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 41 | suppressed |
| Glimepiride | Glimepiride | 40 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 39 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | 12 |
| Simvastatin | Simvastatin | 38 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 30 |
| Celecoxib | Celecoxib | 34 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 21 |
| Lorazepam | Lorazepam | 34 | 13 |
| Pregabalin | Pregabalin | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 13 |
| Potassium Chloride | Potassium Chloride | 30 | 12 |
| Prednisone | Prednisone | 28 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 11 |
| Linzess | Linaclotide | 26 | suppressed |
| Humalog | Insulin Lispro | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Finasteride | Finasteride | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 20 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 12 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Naproxen | Naproxen | 15 | 14 |
| Topiramate | Topiramate | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Synthroid | Levothyroxine Sodium | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.79 · 43 records | Novo Nordisk Inc | AIRSUPRA, Auvelity, Cologuard Collection Kit, ELIQUIS, GEMTESA, Kerendia, LEQVIO, NURTEC ODT, NUZYRA, Ozempic, REXULTI, Rybelsus, Symbravo, TZIELD, The Cologuard Plus Collection Kit, VOQUEZNA, VYNDAQEL, Veozah, Wegovy, XHANCE, ZAVZPRET, ZORYVE | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error